- •Sjögren’s Syndrome
- •Foreword
- •Contents
- •Contributors
- •1.1 Primary Sjögren’s Syndrome
- •1.1.1 Diagnostic Criteria
- •1.1.2 Incidence
- •1.1.3 Prevalence
- •References
- •2.1 Introduction
- •2.2 Genetic Epidemiology of SS
- •2.3 Key Concepts in Genetics, Transcriptomics, and Proteomics
- •2.4 Candidate Genes and SS Pathogenesis
- •2.5 Gene Expression Studies in SS
- •2.6 Protein Expression Studies in SS
- •2.7 Future Directions
- •References
- •3.1 Introduction
- •3.2 Characteristics of Autoimmune Lesions
- •3.3 Epithelial Cells as Key Regulators of Autoimmune Responses
- •3.4 Tissue Injury and Repair
- •3.4.1 Functional Impairment of Glands and Autonomic Nervous System Involvement
- •3.4.2 Extracellular Matrix and Tissue Damage
- •3.5 Pathogenetic Factors
- •3.5.1 Genetic Predisposition
- •3.5.2 Environmental Factors
- •3.5.3 Hormonal
- •3.6 Conclusions/Summary
- •References
- •4.1 Hepatitis C Virus
- •4.2 Hepatitis B Virus
- •4.5 Coxsackieviruses
- •4.6 Herpes Viruses
- •4.7 Human Parvovirus B19
- •4.8 Conclusion
- •References
- •5.1 The Role of T Cells in SjS
- •5.2 The Role of B Cells in SjS
- •5.2.1 The Impact of B Cell Cytokines
- •5.2.2 Ontogeny of B Lymphocytes
- •5.2.3 Subpopulations of B Cells
- •5.2.4 B Cell Monoclonal Expansion
- •5.3 B Cells Are Not Dispensable
- •5.3.1 B Cell Chemokines and Antibody Production
- •5.3.2 Peculiarities of B Cell Products: Cytokines and IgA Autoantibodies
- •5.3.3 Intrinsic Abnormalities of B Cells in Primary SjS
- •5.4 Conclusion
- •References
- •6.1 Introduction
- •6.3 Objective Determination of Salivary Flow
- •6.4 Etiology of Xerostomia
- •6.5 Orofacial Manifestations in SS
- •6.5.1 Salivary Involvement
- •6.5.2 Neurological Involvement
- •6.6 Sialochemical Changes in SS
- •6.7 Hyposalivation: Clinical Features and Complications
- •6.7.1 Clinical Features
- •6.7.2 Examination
- •6.7.3 Clinical Signs of Hyposalivation
- •6.7.4 Effect of Hyposalivation on Quality of Life
- •6.7.5 Management of Hyposalivation
- •6.7.6 Chronic Complications of Hyposalivation
- •Box 6.1: Chronic Complications of Hyposalivation
- •6.7.6.1 Dental Caries
- •Box 6.2: Strategies for Reducing Dental Caries in Patients with Sjögren’s Syndrome
- •6.7.6.2 Periodontal Health
- •6.7.6.3 Oral Functional Impairments
- •6.7.6.4 Oral Infections
- •Box 6.3: Factors Predisposing to Oral Candidiasis
- •6.7.6.6 Angular Stomatitis
- •6.7.6.7 Candidiasis
- •6.7.6.8 Bacterial Sialadenitis
- •6.7.6.9 Oral Ulceration
- •6.8 Salivary Gland Enlargement
- •6.8.1 Box 6.5: Non-Salivary Causes of Salivary Gland Enlargement
- •6.9 Salivary Swelling in SS
- •References
- •Key Websites (Accessed Dec 19, 2009)
- •7.1 Sjögren’s Syndrome: A Disease of the Lacrimal Functional Unit
- •7.2 Components of the Lacrimal Functional Unit
- •7.3 Lacrimal Gland
- •7.4 Conjunctiva
- •7.5 Cornea
- •7.6 Meibomian Glands and Eyelids
- •7.7 Neural Innervation
- •7.8 Mechanisms of Dysfunction
- •7.8.1 Lacrimal Gland
- •7.8.2 Ocular Surface
- •7.9 Diagnosis of Ocular Involvement in Sjögren’s Syndrome
- •7.10 Treatment of LFU Dysfunction
- •References
- •8.1 Introduction
- •8.2 Otologic Manifestations
- •8.3 Sinus and Nasal Manifestations
- •8.4 Laryngopharyngeal and Tracheal Manifestations
- •References
- •9.1 Epidemiology of Fatigue
- •9.2 Assessing Fatigue
- •9.4 Relationship of Fatigue to Cognitive Symptoms and to Depression
- •9.5 Fatigue Viewed From the Physiological Perspective: Relationships Between Fatigue, Sleep Quality, and Neuroendocrine Function
- •9.6 Relationship Between Fibromyalgia and SS
- •9.7 Management of Pain and Fatigue
- •9.8 Summary
- •References
- •10.1 Introduction
- •10.2 Arthralgias and Arthritis
- •10.3 Arthritis: Patterns of Expression
- •10.4 Differential Diagnosis: RA, SLE, and Other Arthropathies
- •References
- •11.1 Introduction
- •11.2 Epidemiology
- •11.3 Skin Changes Encountered in Primary SjS
- •11.3.1 Pruritus
- •11.3.2 Annular Erythema of SjS
- •11.3.3 Eyelid Dermatitis
- •11.3.4 Panniculitis
- •11.3.5 Primary Nodular Cutaneous Amyloidosis
- •11.3.6 B Cell Lymphoma
- •11.4 Skin Changes Encountered in Secondary SjS
- •11.4.1 Skin Changes Associated with Lupus Erythematosus
- •References
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Histopathology
- •12.4 Laboratory Findings
- •12.5 Pathogenesis
- •12.6 Clinical Findings
- •12.7 Skin
- •12.8 Peripheral and Central Nervous System
- •12.9 Other Organs
- •12.10 Vasculitis and Mortality
- •12.11 Treatment
- •References
- •13.1 Introduction
- •13.2 Pericarditis
- •13.3 Myocarditis
- •13.4 Valvular Abnormalities
- •13.5 Diastolic Dysfunction
- •13.6 Atrioventricular Block
- •13.7 Subclinical Atherosclerosis
- •13.8 Pulmonary Arterial Hypertension
- •13.9 Autonomic Cardiovascular Dysfunction
- •13.10 Therapeutic Management
- •13.11 Conclusion
- •References
- •14.1 Introduction
- •14.2 Airway Disease
- •14.2.1 Overview
- •14.2.2 Pathology
- •14.2.3 Imaging Studies
- •14.3 Interstitial Lung Disease
- •14.3.1 Overview
- •14.3.2 Pathology
- •14.3.4 Usual Interstitial Pneumonia
- •14.3.5 Follicular Bronchiolitis
- •14.3.6 Lymphocytic Interstitial Pneumonia
- •14.3.7 Cryptogenic Organizing Pneumonia
- •14.3.8 Clinical Features
- •14.3.9 Imaging Studies
- •14.4 Pleuritis
- •14.5 Diagnosis and Management
- •References
- •15.1 Evaluation of the Sjögren’s Syndrome and Raynaud’s Phenomenon
- •15.2 Management of Raynaud’s Phenomenon
- •15.2.1 Vasodilator Therapy
- •15.2.2 Calcium Channel Blockers
- •15.2.3 Adrenergic Blockers
- •15.2.4 Nitrates
- •15.2.5 Phosphodiesterase Inhibitors
- •15.2.6 Prostacyclins
- •15.2.7 Other Agents
- •15.3 Surgical Options
- •15.3.1 Sympathectomies
- •15.3.2 Management of Critical Digital Ischemia
- •References
- •16.1 Dysphagia
- •16.3 Chronic Gastritis
- •16.5 Association with Celiac Disease
- •16.6 Intestinal Vasculitis
- •16.7 Other Intestinal Diseases
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Primary Biliary Cirrhosis (PBC)
- •17.2.2 Similarities, Differences, and Overlap Among SS and PBC
- •17.2.3 Epithelium Involvement
- •17.2.4 Animal Models
- •17.2.5 Histology and Serology
- •17.3 Autoimmune Hepatitis (AIH)
- •17.4 Hepatitis C Virus (HCV) Infection and Sicca Syndrome
- •17.5 Algorithm for the Diagnosis of Liver Involvement in SS
- •References
- •18.1 Introduction
- •18.3 Involvement of the Pancreas in SjS
- •18.3.1 Clinical Presentation
- •18.3.2 Autoantibodies
- •18.3.3 Pancreatic Enzymes
- •18.3.4 Pathology
- •18.3.5 Imaging Studies of the Pancreas
- •18.4 Autoimmune Pancreatitis
- •18.4.1 Introduction
- •18.4.2 Clinical Features
- •18.4.3 Imaging
- •18.4.4 Serology
- •18.4.5 Pathology
- •18.4.6 Diagnostic Criteria
- •18.5.1 Introduction
- •18.5.2 Nomenclature
- •18.5.3 Clinical Manifestations
- •18.5.4 Serological Issues
- •18.5.5 Pathology
- •18.5.6 Diagnostic Criteria
- •18.6 Conclusions
- •References
- •19.1 Introduction
- •19.2 Interstitial Nephritis in Primary Sjögren’s Syndrome
- •19.2.1 Historical Aspects
- •19.2.2 Clinical Features
- •19.2.3 Histology
- •19.2.4 Pathogenesis
- •19.2.5 Differential Diagnosis
- •19.2.6 Treatment
- •19.3 Glomerulonephritis in Primary Sjögren’s Syndrome
- •19.3.1 Historical Aspects
- •19.3.2 Clinical Features
- •19.3.3 Histology
- •19.3.4 Pathogenesis
- •19.3.5 Differential Diagnosis
- •19.3.6 Treatment
- •19.4 Painful Bladder Syndrome/Interstitial Cystitis and Primary Sjögren’s Syndrome
- •19.4.1 Historical Aspects
- •19.4.2 Clinical, Cytoscopic, and Histologic Features
- •19.4.3 Pathogenesis and Association with Sjögren’s Syndrome
- •19.4.4 Differential Diagnosis
- •19.4.5 Treatment
- •References
- •20.2 Cerebral Lesions
- •20.3 Differential Diagnosis with Multiple Sclerosis, Neuromyelitis Optica, and Antiphospholipid Syndrome
- •20.4 Cranial Nerve Involvement
- •20.5 Diagnostic Algorithm of SS Patient with CNS Lesions, Myelitis, Meningitis
- •References
- •21.3 Sensorimotor Demyelinating Polyneuropathy (CIDP)
- •21.4 Multiple Mononeuropathy or Mononeuritis Multiplex
- •21.5 Sensory Ataxic Neuronopathy
- •21.6 Small Fiber Painful Sensory Neuropathy
- •21.7 Restless Leg Syndrome
- •References
- •22.1 Introduction
- •22.2 Pathogenesis of Autonomic Dysfunction in pSS
- •22.3 Diagnostic Tests
- •22.4 Parasympathetic and Sympathetic Disorders
- •22.4.1 Secretomotor Disorder
- •22.4.2 Urinary Disorder
- •22.4.3 Gastrointestinal Disorder
- •22.4.4 Pupillomotor Disorder
- •22.4.5 Orthostatic Intolerance
- •22.4.6 Vasomotor Disorder
- •22.5 Diagnostic Algorithm of pSS Patient with Autonomic Dysfunction
- •22.6 Treatment
- •References
- •23.1 Introduction
- •23.5 Prolactin and Sjögren Syndrome
- •23.7 Perspectives of Hormonal Treatment on Sjögren Syndrome
- •23.8 Conclusions
- •References
- •24.1 Introduction
- •24.2 Gynecological Manifestations in Sjögren’s Syndrome
- •24.3.1 Epidemiology and Clinical Features of NLS and Congenital Heart Block (CHB)
- •24.3.2 Maternal and Fetal Outcomes in NLS
- •24.3.3 Diagnosis
- •24.3.4 Risk Factors
- •24.3.5 Pathogenesis of Congenital Heart Block
- •References
- •25.1 Introduction
- •25.2 Serum Proteins
- •25.2.1 Acute Phase Reactants
- •25.2.2 Gammaglobulins
- •25.2.2.1 Polyclonal Hypergammaglobulinemia
- •25.2.2.3 Circulating Monoclonal Immunoglobulins
- •25.3 Hematological Abnormalities
- •25.3.1 Normocytic Anemia
- •25.3.2 Autoimmune Hemolytic Anemia
- •25.3.3 Aplastic Anemia
- •25.3.4 Pure Red Cell Aplasia
- •25.3.5 Myelodysplasia
- •25.3.6 Pernicious Anemia
- •25.3.7 Leukopenia
- •25.3.8 Lymphopenia
- •25.3.9 Neutropenia
- •25.3.10 Eosinophilia
- •25.3.11 Thrombocytopenia
- •25.4 Conclusions
- •References
- •26.2 Questionnaires
- •26.3 Ocular Tests
- •26.3.1 Schirmer Test
- •26.3.2 Vital Dyes
- •26.3.3 Rose Bengal
- •26.3.4 Fluorescein
- •26.3.5 Lissamine Green
- •26.3.7 Tear Osmolarity
- •26.3.8 Tear Meniscus
- •26.3.9 Tear Proteins
- •26.3.10 Ferning Test
- •26.3.11 Ocular Cytology
- •26.4 Oral Tests
- •26.4.1 Wafer Test
- •26.4.2 Whole Saliva Flow Collection
- •26.4.3 Saxon Test
- •26.4.5 Impression Cytology
- •26.5 Conclusion
- •References
- •27.1 Salivary Scintigraphy
- •27.2 Sialography
- •27.3 Ultrasound
- •27.4 Tomography
- •27.5 Magnetic Resonance
- •27.6 Salivary Gland Biopsy
- •27.6.1 Labial Gland Biopsy
- •27.6.2 Daniels’ Technique
- •27.6.3 Punch Biopsy
- •27.6.4 Major Salivary Gland Biopsy
- •27.6.5 Lacrimal Gland Biopsy
- •27.6.6 Focus Score
- •27.7 Is There an Alternative to Labial Salivary Gland Biopsy?
- •References
- •28.1 Antinuclear Antibodies
- •28.3 Antibodies Against Nonnuclear Antigens
- •28.7 Antiphospholipid Antibodies
- •28.9 Anticentromere Antibodies
- •28.12 Rheumatoid Factor and Cryoglobulins
- •28.13 Complement
- •28.14 Conclusion
- •References
- •29.1 Introduction
- •29.2 Historical Overview and Sets of Criteria
- •29.3 Preliminary European Criteria
- •References
- •30.1 Introduction
- •30.2 Clinical and Serological Peculiarities of Sjögren’s Syndrome
- •30.3 Assessment of Disease Activity or Damage in Systemic Autoimmune Diseases
- •30.4 Methodological Procedures to Develop Disease Status Criteria
- •30.5 Development of Disease Status Indices for Sjögren’s Syndrome
- •30.5.1 The Italian Approach
- •30.5.2 The British Approach
- •30.5.3 The EULAR Initiative
- •References
- •31.1 Introduction
- •31.3 Other Generic QoL/HRQoL Measures
- •31.6 Predictors of QoL and HRQoL (WHOQoL) in PSS
- •31.7 Therapeutic Interventions
- •31.8 Conclusions and Summary
- •References
- •32.1 Introduction
- •32.2 SS Associated with Systemic Lupus Erythematosus (SLE)
- •32.3 SS Associated with Rheumatoid Arthritis (RA)
- •32.5 SS Associated with Other Systemic Autoimmune Diseases
- •32.5.1 Mixed Connective Tissue Disease
- •32.5.2 Systemic Vasculitis
- •32.5.3 Antiphospholipid Syndrome (APS)
- •32.5.4 Sarcoidosis
- •32.6.1 SS Associated with Autoimmune Thyroiditis
- •32.6.2 SS Associated with Autoimmune Liver Disease
- •32.6.3 Association of SS with Coeliac Disease
- •32.7 Conclusions
- •References
- •33.1 Introduction
- •33.2 Methodological Considerations
- •33.3 Primary Sjögren’s Syndrome and Lymphoma
- •33.3.1 Risk Levels
- •33.3.2 Lymphoma Subtypes
- •33.4 Prediction of Lymphoma
- •33.4.1 Can We Tell Who Will Develop Lymphoma and When This May Occur?
- •33.4.2 Established Risk Factors
- •33.4.3 Recently Proposed Newer Risk Factors
- •33.5 Pathogenetic Mechanisms
- •33.6 Medication and Risk of Lymphoma in SS
- •33.7 Associated Sjögren’s Syndrome and Lymphoma
- •33.8 Other Cancers in SS
- •33.9 Conclusion
- •References
- •34.1 Introduction
- •34.2 Mortality and Causes of Death in pSS
- •34.4 Conclusions
- •References
- •35.1 Introduction
- •35.2 General Considerations
- •35.3.1 Keratoconjunctivitis Sicca
- •35.3.2 Xerostomia
- •35.3.3 Systemic Dryness
- •35.3.4 Extraglandular Manifestations
- •35.4 Diagnosis
- •35.4.2 Diagnostic Methods
- •35.4.2.1 Keratoconjunctivitis Sicca
- •35.4.2.2 Xerostomia
- •35.4.2.3 Salivary Gland Biopsy
- •35.4.2.4 Immunological Tests
- •35.4.2.5 Other Laboratory Findings
- •35.5 Comorbidities and Occupational Disability
- •35.6 Treatment
- •35.6.1 Keratoconjunctivitis Sicca
- •35.6.2 Xerostomia
- •35.6.3 Management of Extraglandular Features
- •35.7 When to Refer to a Specialist
- •References
- •36.1 Background
- •36.2 General Approach to Dry Mouth
- •36.3 Additional Dental Needs of the SjS Patient
- •36.3.1 Background
- •36.4 Particular Oral Needs of the SjS Patient to Be Assessed by the Rheumatologist
- •36.5 Use of Secretagogues
- •36.5.1 Other Cholinergic Agonists
- •36.5.2 Additional Topical Treatments
- •36.5.3 Systemic Therapy
- •36.6 Oral Candidiasis
- •36.7 Treatment and Management of Cutaneous Manifestations
- •36.7.1 Treatment of Dry Skin in SjS Is Similar to Managing Xerosis in Other Conditions
- •36.7.2 Vaginal Dryness
- •36.7.3 Special Precautions at the Time of Surgery
- •References
- •37.1 Introduction
- •37.2 Marginal Zone (MZ) Lymphomas
- •37.2.1 Extranodal Marginal Zone Lymphomas of MALT Type
- •37.2.2 Therapeutic Approaches of MALT Lymphomas
- •37.2.4 Managing NMZL
- •37.3.1 Histology and General Considerations
- •37.3.2 Treatment of DLBCL
- •37.4 Conclusions
- •References
- •38.1 Introduction
- •38.2 Antimalarials
- •38.4 Glucocorticoids
- •38.5 Azathioprine
- •38.6 Cyclophosphamide
- •38.7 Methotrexate
- •38.8 Cyclosporine
- •38.9 Conclusion
- •References
- •39.3 Mycophenolic Acid
- •39.4 Mizoribine
- •39.5 Rebamipide
- •39.6 Diquafosol
- •39.7 Cladribine
- •39.8 Fingolimod
- •References
- •40.1.2.1 Serum BAFF in SS
- •40.1.3 BAFF Is Secreted by Resident Cells of Target Organs of Autoimmunity
- •40.2 Rituximab in SS
- •40.2.1 The Different Studies Assessing Rituximab in SS
- •40.2.2 Safety of Rituximab
- •40.2.3 Increase of BAFF After Rituximab Therapy
- •40.3.1 Epratuzumab
- •40.4 Conclusion
- •References
- •41.1 Introduction
- •41.2 Cytokine Targeted Therapies
- •41.2.2 Etanercept
- •41.2.3 Interferon Alpha
- •41.2.4 Emerging Anticytokine Therapies
- •41.3 T Cell Targeted Therapies
- •41.3.1 Efalizumab
- •41.3.2 Alefacept
- •41.3.3 Abatacept
- •41.4 Conclusion
- •References
- •42.1 Introduction
- •42.2 Progression and Disease Activity in SjS
- •42.2.1 Saliva
- •42.2.2 Serum
- •42.2.3 Labial or Parotid Tissue
- •42.3 Molecular Targets for Potential Therapeutic Interventions
- •42.3.1 Interferons
- •42.3.2 Cytokines
- •42.3.3 B Cell Activating Factors
- •42.3.4 B and T Cell Receptors
- •42.3.4.1 Rituximab
- •42.3.4.2 Epratuzumab
- •42.3.4.3 Abatacept
- •42.4 Gene Therapy
- •42.5 Stem Cell Therapy
- •42.6 Conclusion
- •References
- •Index
Chapter 7
Ocular Involvement
Stephen C. Pflugfelder, Karyn Siemasko, and Michael E. Stern
Contents
7.1 |
Sjögren’s Syndrome: A Disease of the Lacrimal Functional Unit.............................. |
107 |
|
7.2 |
Components of the Lacrimal Functional Unit.............................................................. |
108 |
|
7.3 |
Lacrimal Gland ............................................................................................................... |
109 |
|
7.4 |
Conjunctiva...................................................................................................................... |
109 |
|
7.5 |
Cornea.............................................................................................................................. |
110 |
|
7.6 |
Meibomian Glands and Eyelids..................................................................................... |
110 |
|
7.7 |
Neural Innervation.......................................................................................................... |
110 |
|
7.8 |
Mechanisms of Dysfunction ........................................................................................... |
111 |
|
|
7.8.1 |
Lacrimal Gland ..................................................................................................... |
111 |
|
7.8.2 |
Ocular Surface....................................................................................................... |
111 |
7.9 |
Diagnosis of Ocular Involvement in Sjögren’s Syndrome........................................... |
112 |
|
7.10 |
Treatment of LFU Dysfunction...................................................................................... |
113 |
|
References |
................................................................................................................................. |
117 |
|
7.1Sjögren’s Syndrome: A Disease of the Lacrimal Functional Unit
Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by diminished production and secretion of tears by the lacrimal glands and saliva by the salivary glands resulting in keratoconjunctivitis sicca and stomatitis sicca, respectively. The estimated prevalence of primary SS (pSS) in the USA is 1.3 million individuals
S.C. Pflugfelder (*) • M.E. Stern
Department of Ophthalmology¸ Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA
K. Siemasko
Biological Sciences, Allergan, Inc, Irvine, CA, USA
M. Ramos-Casals et al. (eds.), Sjögren’s Syndrome, |
107 |
DOI 10.1007/978-0-85729-947-5_7, © Springer-Verlag London Limited 2012 |
|
108 |
S.C. Pflugfelder et al. |
and the prevalence is 10–20 greater in women [1–4]. Primary SS is an autoimmune inflammation to self-antigens in the lacrimal and salivary glands in the absence of a defined systemic autoimmune disease. Multiple factors, including defective immunoregulation, genetic background, and environmental insults (e.g., desiccating stress and viral infection) have been proposed in the pathogenesis of glandular and mucosal autoimmunity in pSS [5–7]. In secondary SS, salivary and lacrimal gland inflammation develops in the presence of an existing autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, or scleroderma [8, 9].
The main and accessory lacrimal glands, along with the conjunctiva, cornea, meibomian glands, and their interconnecting neural network comprise the lacrimal functional unit (LFU) [10]. SS causes profound dysfunction of multiple components of the LFU, resulting in severe chronic dry eye [11].
7.2Components of the Lacrimal Functional Unit
The LFU is essential in maintaining a homeostasis on the ocular surface by maintaining a stable tear film of normal composition. Factors in healthy tears support and protect the conjunctiva and cornea. The tear fluid contains numerous proteins, including enzymes, growth factors (e.g., epidermal growth factors) and antimicrobial factors such as secretory IgA, cystatins, and defensins. The tear film is currently considered to be a hydrated mucin gel [12]. It is composed of three major components, including mucins secreted by the stratified ocular surface epithelial and conjunctival goblet cells, aqueous produced by the lacrimal glands, and lipids secreted by the meibomian glands [13].The conjunctiva and corneal epithelia express membrane-tethered mucins 1, 2, and 16 that make up the glycocalyx that lubricates the ocular surface and binds the tear mucin layer to the hydrophobic epithelial cell surface [14].
MUC5AC is a soluble mucin secreted by conjunctival goblet cells, and the lacrimal glands contribute MUC-7 to the tear film [15–17]. Mucins are thought to clear pathogens, provide ocular surface lubrication, and serve as a barrier function to microbial invasion and inflammatory cellular infiltration of the ocular surface [18, 19]. The aqueous component secreted by the lacrimal glands contains trophic and protective factors including growth factors, immunoglobulin A, lactoferrin, lysozyme, defensins, interleukin-1 receptor antagonist, and electrolytes [13]. Finally, the meibomian glands secrete the lipid layer that functions to decrease tear film evaporation. A stable tear film keeps the cornea surface smooth, continuously lubricates the ocular surface, protects it from microbial infections and environmental insults, and delivers factors to maintain well-being of the epithelial surface. As the primary refracting surface of the eye, a healthy and stable tear film is essential for high quality vision. Tear film instability and the corneal epithelial disease that develops in dry eye can decrease functional vision and contrast sensitivity [20–22]. Consequently, many SS patients experience blurred and fluctuating vision, visual fatigue, and severe photophobia [22, 23]. Even small alterations in tear composition resulting from disease of the LFU in SS can produce deleterious consequences for the ocular surface.
7 Ocular Involvement |
109 |
7.3Lacrimal Gland
The lacrimal gland secretes tears produced by acinar and ductal epithelia on demand. The main lacrimal gland, consisting of the palpebral and orbital lobes, is located in the superior temporal orbit. The accessory lacrimal glands consist of the glands of Krause that are located in the upper fornix and glands of Wolfring in the superior conjunctiva just above the upper edge of the tarsus. The majority of tear secretion by the lacrimal glands is reflexive, in response to neural stimulation [24]. Innervating parasympathetic cholinergic nerves release acetylcholine that binds to the muscarinic 3 acetylcholine receptor (M3R) located on the basolateral cell membranes of lacrimal gland secretory epithelia [25, 26]. In addition, the cholinergic neurotransmitter VIP interacts with the type I and type II VIP receptors on these cells [27]. Binding of acetylcholine and VIP to their respective receptors activates signaling pathways, leading to the fusion of secretory granules with the apical membrane, membrane ion transporter activation, and ion pump insertion to coordinate electrolyte secretion and regulate tear osmolarity. Sympathetic nerves also innervate the lacrimal gland. The binding of norepinephrine to a1- and b-adrenergic receptors increases Ca+ flux into the cytosol [28]. Finally, the neurotransmitters substance P and calcitonin gene-related peptide (CGRP) are released by sensory nerves in the lacrimal glands [25].
Proteins secreted by the lacrimal gland are synthesized and mannosylated in the endoplasmic reticulum. As the proteins move through the Golgi complex, the carbohydrate groups are modified. While in the trans-Golgi apparatus, proteins are assembled into transport vesicles and packaged into secretory vesicles. The lacrimal gland contains T and B lymphoid follicles and IgA-producing plasma cells that surround the acini. These lymphocytes make up what has been referred to as the mucosal-associated lymphoid tissue (MALT).
7.4Conjunctiva
The conjunctiva covers the majority of the ocular surface and functions as the major support system for the cornea by producing tear components and supplying immune and inflammatory cells [29]. The conjunctiva has three topographic zones: bulbar, palpebral, and forniceal. The conjunctiva forms a continuous mucosal surface over these three zones. The bulbar conjunctiva covers the anterior surface of the globe, the palpebral conjunctiva lines the inner surface of the eyelids, and the forniceal conjunctiva connects the palpebral and bulbar conjunctiva. The conjunctiva consists of two components, the stratified nonkeratinized secretory epithelium and the underlying stroma. Goblet cells comprise approximately 5–20% of conjunctival epithelial cells. These specialized cells secrete MUC5AC mucin and TGF-b2 into the tears [30]. The conjunctiva is also a source of the sIgA found in tears [31]. The lamina propria of the conjunctiva is vascularized and contains numerous bone marrow-derived cells, including macrophages, mast cells, lymphocytes, plasma cells, and dendritic cells [31].
110 |
S.C. Pflugfelder et al. |
The adaptive arm of the ocular surface immune response is located in the conjunctiva and is called the conjunctival-associated lymphoid tissue (CALT). The CALT is found mainly in the palpebral conjunctiva and consists of intraepithelial lymphocytes, lymphoid follicles located just below the epithelium and lymphatics, and blood vessels [32]. The CALT initiates and regulates immune responses by sampling and processing antigens on the ocular surface. The CALT is now accepted as a component of the overall mucosa-associated lymphoid tissue (MALT) [31]. Knop and Knop have proposed that the lacrimal drainage-associated lymphoid tissue, lymphocytes in the lacrimal glands, and the CALT all serve as a defensive unit for the ocular surface called the eye-associated lymphoid tissue (EALT) [31].
7.5Cornea
The cornea is endowed with the highest density of sensory nerve endings of any tissue in the body [33]. The cornea is a unique clear tissue that is the most powerful lens in the eye. Its clarity is due to the surface tear layer, specialized non-keratiniz- ing epithelium with tight junctions, keratocytes, organized collagen lamella, and endothelial cells that pump fluid out of the cornea. The sensory nerve endings that terminate in the corneal epithelium constantly monitor the environment and signal the central nervous system to regulate tear secretion by the lacrimal functional unit in response to environmental challenge. In the healthy state, proteases in the tear film regulate turnover of the differentiated apical cornea epithelial cells. Increased tear protease activity in SS accelerates epithelial turnover and disrupts the protective epithelial barrier [34]. The cornea contains resident MHC class II-negative dendritic cells. These dendritic cells are capable of expressing MHC class II and traveling to the draining lymph nodes to initiate immune reactions in response to proinflammatory stimuli such as increased tear cytokines in SS [35–38].
7.6Meibomian Glands and Eyelids
The meibomian glands secrete lipids that retard tear film evaporation and stabilize the tear film. Meibomian glands are located in the tarsal plates of the upper and lower eyelids. Lipid is released into the tears from the meibomian gland ducts that are located on the lid margins. Over 100 different lipids are secreted by the meibomian gland that include polar lipids, wax esters, free fatty acids, and cholesterol [39].
7.7Neural Innervation
An integrated neural network connects the lacrimal glands, cornea, conjunctiva, and the meibomian glands [10]. The primary role of the LFU is to maintain homeostasis on ocular surface. The LFU is regulated by sensory, sympathetic, and parasympathetic
